DNA Vaccination for HIV-1 and SIV

Control of the worldwide AIDS epidemic will only be achieved with a safe and effective prophylactic HIV-1 vaccine. DNA vaccination has recently emerged as a promising vaccine modality that can elicit both humoral and cellular immune responses. HIV-1- and SIV-specific immune responses have been elicited by DNA vaccines in both mice and nonhuman primates. However, these immune responses have not been capable of protecting nonhuman primates against pathogenic AIDS virus challenges. A number of approaches are therefore being investigated to augment DNA vaccine-elicited immune responses.

[1]  Todd M. Allen,et al.  Effective Induction of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Macaques by Using a Multiepitope Gene and DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccination Regimen , 1999, Journal of Virology.

[2]  J. Fukushima,et al.  Immunization of RANTES expression plasmid with a DNA vaccine enhances HIV-1-specific immunity. , 1999, Clinical immunology.

[3]  D. Montefiori,et al.  Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations , 1999, Nature Medicine.

[4]  A. Chalian,et al.  Intracellular adhesion molecule-1 modulates beta-chemokines and directly costimulates T cells in vivo. , 1999, The Journal of clinical investigation.

[5]  L. Weinberger,et al.  Dramatic Rise in Plasma Viremia after CD8+ T Cell Depletion in Simian Immunodeficiency Virus–infected Macaques , 1999, The Journal of experimental medicine.

[6]  N. Haigwood,et al.  Protection from pathogenic SIV challenge using multigenic DNA vaccines. , 1999, Immunology letters.

[7]  E. Okada,et al.  IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. , 1999, Vaccine.

[8]  D. Montefiori,et al.  Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. , 1999, Science.

[9]  J. Fukushima,et al.  Macrophage inflammatory protein‐1α (MIP‐1α) expression plasmid enhances DNA vaccine‐induced immune response against HIV‐1 , 1999 .

[10]  D. Weiner,et al.  Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial. , 1999, Clinical immunology.

[11]  A. Chalian,et al.  Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[12]  S. Kent,et al.  Enhanced T-Cell Immunogenicity and Protective Efficacy of a Human Immunodeficiency Virus Type 1 Vaccine Regimen Consisting of Consecutive Priming with DNA and Boosting with Recombinant Fowlpox Virus , 1998, Journal of Virology.

[13]  A. Chalian,et al.  Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes. , 1998, Vaccine.

[14]  D. Montefiori,et al.  Studies of the Neutralizing Activity and Avidity of Anti-Human Immunodeficiency Virus Type 1 Env Antibody Elicited by DNA Priming and Protein Boosting , 1998, Journal of Virology.

[15]  K. Okuda,et al.  Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts. , 1998, Virology.

[16]  A. Chalian,et al.  CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. , 1998, The Journal of clinical investigation.

[17]  A. Craiu,et al.  Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. , 1998, Journal of immunology.

[18]  P. Shapshak,et al.  Intranasal administration of human immunodeficiency virus type‐1 (HIV‐1) DNA vaccine with interleukin‐2 expression plasmid enhances cell‐mediated immunity against HIV‐1 , 1998, Immunology.

[19]  D. Weiner,et al.  First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. , 1998, The Journal of infectious diseases.

[20]  A. Fauci,et al.  HIV/AIDS in 1998--gaining the upper hand? , 1998, JAMA.

[21]  N. Letvin.  Progress in the development of an HIV-1 vaccine. , 1998, Science.

[22]  E. Sandström,et al.  Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients , 1998, The Lancet.

[23]  Marion Becker,et al.  Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara , 1998, Nature Medicine.

[24]  M A Nowak,et al.  Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. , 1998, Science.

[25]  A. McMichael,et al.  Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. , 1998, Vaccine.

[26]  A. Chalian,et al.  Modulation of amplitude and direction of in vivo immune responses by co‐administration of cytokine gene expression cassettes with DNA immunogens , 1998, European journal of immunology.

[27]  E. Rosenberg,et al.  Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. , 1997, Science.

[28]  M. McElrath,et al.  Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. , 1997, The New England journal of medicine.

[29]  J. Miyazaki,et al.  Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. , 1997, Journal of immunology.

[30]  D. Montefiori,et al.  Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Weiner,et al.  Genetic immunization: a new era in vaccines and immune therapeutics , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  J. Clements,et al.  Gene gun‐based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV , 1997, Immunology and cell biology.

[33]  A. Chalian,et al.  Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes , 1997, Nature Biotechnology.

[34]  N. Letvin,et al.  Anti-HIV env immunities elicited by nucleic acid vaccines. , 1997, Vaccine.

[35]  J. Kim,et al.  Development of a multicomponent candidate vaccine for HIV-1. , 1997, Vaccine.

[36]  N. Letvin,et al.  HIV-1 env DNA vaccine administered to rhesus monkeys elicits MHC class II-restricted CD4+ T helper cells that secrete IFN-gamma and TNF-alpha. , 1997, Journal of immunology.

[37]  R. Kennedy.  DNA vaccination for HIV , 1997, Nature Medicine.

[38]  D. Weiner,et al.  Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination , 1997, Nature Medicine.

[39]  J. Kim,et al.  In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. , 1997, Journal of immunology.

[40]  J. Shiver,et al.  Humoral and Cellular Immunities Elicited by HIV-1 DNA Vaccination , 1996 .

[41]  J. Mullins,et al.  Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys , 1996, Journal of virology.

[42]  J. Mullins,et al.  Simian Immunodeficiency Virus DNA Vaccine Trial in Macaques , 1995, Journal of virology.

[43]  N. Letvin,et al.  Vaccination of mice and nonhuman primates using HIV-gene-containing DNA. , 1996, Antibiotics and chemotherapy.

[44]  R. Webster,et al.  DNA vaccines. , 1996, AIDS research and human retroviruses.

[45]  J. Shiver,et al.  Cytotoxic T Lymphocyte and Helper T Cell Responses following HIV Polynucleotide Vaccination , 1995, Annals of the New York Academy of Sciences.

[46]  J. Sodroski,et al.  T cell receptor V beta repertoire in an acute infection of rhesus monkeys with simian immunodeficiency viruses and a chimeric simian- human immunodeficiency virus , 1995, The Journal of experimental medicine.

[47]  D. Fuller,et al.  Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice. , 1995, Virology.

[48]  Z. Xiang,et al.  Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. , 1995, Immunity.

[49]  G. Shaw,et al.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection , 1994, Journal of virology.

[50]  Persephone Borrow,et al.  Major expansion of CD8+ T cells with a predominant Vβ usage during the primary immune response to HIV , 1994, Nature.

[51]  D. Ho,et al.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome , 1994, Journal of virology.

[52]  D. Montefiori,et al.  Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques , 1994, Journal of virology.

[53]  V. Srikantan,et al.  DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type 1 in mice and nonhuman primates. , 1993, DNA and cell biology.

[54]  Bin Wang,et al.  Gene inoculation generates immune responses against human immunodeficiency virus type 1. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[55]  J. Ulmer,et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.

[56]  N. Letvin,et al.  Simian immunodeficiency virus-specific CD8+ lymphocyte response in acutely infected rhesus monkeys , 1993, Journal of virology.

[57]  D. Tang,et al.  Genetic immunization is a simple method for eliciting an immune response , 1992, Nature.

[58]  G. Acsadi,et al.  Direct gene transfer into mouse muscle in vivo. , 1990, Science.

[59]  Lewicki,et al.  Virus-Specific CD 8 + Cytotoxic T-Lymphocyte Activity Associated with Control of Viremia in Primary Human Immunodeficiency Virus Type 1 Infection , 2022 .